Beginning with the end in mind: how early plasmid design and CDMO partnership can set you up for success in cell or gene therapy manufacturing

Richard Parker-Manuel, PhD, is a Group Leader for Plasmid Engineering and Production at OXGENE, A WuXi Advanced Therapies Company. He has twenty years’ experience in molecular biology with nearly seven years the cell gene therapy space. oversees design engineering of adeno associated virus lentivirus vector plasmids variety clients. also involved several R&D initiatives aim making OXGENE’s excellent vectors even better.Qian Liu, joined OXGENE July 2017 as Cell Line Scientist. She background biology, was then gradually promoted to lead all biomanufacturing services provide. Prior joining Qian postdoctoral researcher field Regenerative Medicine, bioartificial liver development stem differentiation mechanism investigation Loughborough University Nottingham, respectively. obtained her PhD Molecular Nutrition from Nottingham.